In this section EMI's lure for allstar act is 35m Marconi hits target. There were whispers that Morgan Stanley had been a big buyer. The US bank did reveal that it was soon to start coverage on the stock. Despite its sluggish performance, Oxford Glycosciences has been the subject of considerable enthusiasm from analysts.
Genomics involves matching up genes to their progeny - proteins.
Oxford Glycosciences has a library of proteins, which it licenses to drug companies. Alongside this library is an in-house drug development operation. The lead product is a drug for Gaucher's disease - a digestive complaint largely affecting Ashkenazi Jews, which causes the liver and spleen to swell. The company expects to file this with US regulators this summer, with a commercial launch possible within a year. Oxford Glycosciences is a genuine pioneer in its field - it has a head start on its competitors in proteomics.